TLDR:
- CMPS hovers near $6 as Compass sets Feb. 17 release for Phase 3 COMP360 data.
- Compass schedules COMP005 and COMP006 updates on COMP360 psilocybin for TRD.
- CMPS traders get Phase 3 readouts at 6:30 a.m. ET, then a management webcast.
- COMP360 trial data lands Feb. 17, as Compass targets faster access in mental health.
- Compass highlights Breakthrough Therapy and UK ILAP status ahead of new TRD data.
Compass Pathways (CMPS) shares closed at $5.81 and then traded near $6.00 after hours. The move kept CMPS in focus ahead of a scheduled clinical update. The company plans to release new Phase 3 data tied to its COMP360 program for treatment-resistant depression.
CMPS price action ties to a scheduled Feb. 17 data drop
Compass Pathways will publish new clinical data on February 17 at 6:30 a.m. ET. Soon after, management will host a live audio webcast at 8:00 a.m. ET. Together, the release and webcast concentrate attention into a single morning window and set a defined timetable for follow-through.
The company will report results from two ongoing Phase 3 studies evaluating COMP360. It will disclose new clinical data from Part A and Part B of COMP005. It will also disclose new clinical data from Part A of COMP006, which expands the set of readouts coming from the Phase 3 program.
Compass will keep a replay of the webcast available for 30 days. That extended access gives market participants more time to review the discussion and the presented materials. As a result, the update can drive continued coverage beyond the first trading session after the release.
Phase 3 COMP005 and COMP006 extend COMP360 evaluation in TRD
Compass developed COMP360 as a synthetic, proprietary formulation of psilocybin. The Phase 3 program targets treatment-resistant depression (TRD), a condition where patients do not respond adequately to available therapies. Because TRD creates persistent care gaps, companies often treat Phase 3 progress as a key proof point for broader adoption.
COMP005 and COMP006 represent Compass Pathways’ pivotal studies in this setting. The company plans to report multiple segments from these trials in one coordinated update, which keeps the dataset linked under one event. The release structure also suggests Compass designed the program to capture separate readouts that can support a fuller view of outcomes.
Compass framed the announcement around “new clinical data,” and that wording signals more than a timing update. The market will receive results tied to specific trial parts, and those data points can shape near-term narrative. In addition, the readout may influence how stakeholders view the next steps for COMP360 in late-stage development.
Company context highlights regulatory designations and expansion goals
Compass Pathways positions itself as a biotechnology company focused on evidence-based innovation in mental health. It aims to accelerate patient access to new treatment options and to improve care for serious conditions. The company also emphasizes a treatment approach that targets rapid and durable responses, which remains a major goal in depression therapy.
COMP360 holds Breakthrough Therapy designation from the U.S. Food and Drug Administration for TRD. It also holds the Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. These regulatory designations can support closer engagement with authorities and can help clarify development expectations during advanced clinical stages.
Compass Pathways is headquartered in London and maintains offices in New York. The company continues to build its profile around clinical execution, development timelines, and regulatory alignment. Therefore, the Feb. 17 data release stands as a near-term test of how Compass converts its Phase 3 work into clear clinical progress for TRD.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
